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Mitochondrial Respiratory Chain Disorders (MRCD) are a het-
erogeneous group of disorders that share the involvement of the 
cellular bioenergetic machinery due to molecular defects affect-
ing  the  mitochondrial  oxidative  phosphorylation  system  (OX-
PHOS). 
Clinically, they usually involve multiple tissues although they 
tend  to  mainly  affect  nervous  system  and  skeletal  muscle. 
Cardiological manifestations are frequent and include hyper-
trophic  or  dilated  cardiomyopathies  and  heart  conduction 
defects, being part of adult or infantile multisystemic mito-
chondrial disorders or, less frequently, presenting as isolated 
clinical condition. 
The aim of this review is to update the cardiological manifesta-
tions in both adult and infantile mitochondrial disorders going 
briefly over mitochondrial genetics. 
Cardiac involvement is a common feature associated with early 
and late onset forms of MRCD. In particular cases, these con-
ditions  should  be  considered  into  the  diagnostic  algorithm  of 
idiopathic cardiomyopathies. Physicians strictly related with this 
disorders need to be aware of heart complications and therefore 
periodical  cardiological  examinations  should  be  performed  in 
such  patients.  Finally,  therapeutic  strategies  are  suggested  to 
treat cardiac disorders in MRCD 
Key words: Mitochondrial cardiomyopathies, molecular diagnosis, 
therapy
Introduction
The mitochondria are complex organelles responsi-
ble for many essential functions of the cellular machin-
ery. They are primarily involved in the production of en-
ergy, assembling ATP molecules that are the final product 
of the respiratory chain (1). However, mitochondria also 
have an important role in apoptosis through the activation 
of the caspases cascade (2, 3), thus participating to neuro-
degenerative processes (4,5). Other mitochondrial func-
tions include heat production (6) and the transmission of 
maternal genetic traits (7, 8). 
The respiratory chain is composed of five enzymatic 
multimeric complexes (I, II, III, IV and V), embedded in 
the inner mitochondrial membrane. In addition, coenzyme 
Q (a lipoidal quinone) and cytochrome c are involved in 
mitochondrial respiration, serving as ‘electron shuttles’ 
between the complexes (9, 10). Most of the cellular en-
ergy is produced by mitochondria making them a target 
for the development of bioenergetic tissues deficits. Mito-
chondrial respiratory chain disorders (MRCD) are caused 
by sporadic or inherited mutations in mitochondrial DNA 
(mtDNA) or nuclear DNA (nDNA). 
Mitochondria  are  the  only  cellular  organelles  that 
possess their own genetic material, but their functions are 
crucially dependent on a wide array of proteins encoded 
by nuclear genes. Therefore, mitochondrial physiology 
and pathology are determined by both genomes (11). 
Mitochondrial genetics and cardiological disorders
The human mtDNA is a 16,569-bp, double-stranded, 
circular molecule containing 37 genes, 24 of which partici-
pate in the translation mechanism (2 rRNA’s - 22 tRNA´s). 
The 13 remaining genes left are responsible for the syn-
thesis of respiratory chain subunits. Hence, among the ap-
proximately 900 genes that participate in the function of the 
organelle, only a few are localized in the mtDNA, whereas 
the remainder are in the nDNA. This explains why about 
50% of adults and 80-90% of children, suspected to have 
a mitochondrial disease on the basis of biochemical and/or 
morphological features, remain genetically undiagnosed. 
Indeed, it is reasonable to believe that most mitochondrial 
diseases are caused by undiscovered nuclear genes (12-14). 
On the other hand, mtDNA mutations, which were stud-
ied in greater details, obey to different genetic rules than 
those applied to “mendelian” disorders (15). First, mtDNA 
is maternally inherited as sperm mitochondria’s are elimi-
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nated early in embryogenesis. Hence, mtDNA will only be 
transmitted through the maternal line. Second, there are 
multiple copies of mtDNA in each cell: homoplasmy refers 
to the situation in which all mtDNA copies are identical. If 
two or more sequence variants exist in a cell or individual, 
that condition is referred to as heteroplasmy. If deleteri-
ously mutant (i.e, pathogenic) and normal mtDNA coex-
ist in the same cell, the respiratory chain function will not 
be impaired as long as there is sufficient normal mtDNA 
to overcome the effects of mutant DNA. If, however, the 
ratio of mutant to normal mtDNA exceeds a certain criti-
cal threshold, then the respiratory chain function will be 
impaired. The threshold at which symptoms will manifest 
depends on the tissue involved. Skeletal muscle (especial-
ly extraocular muscles) brain, heart, retina, renal tubular 
cells, and auditory cells of the organ of Corti are the most 
common tissues affected. Third, mitotic segregation of the 
multiple existing copies of mtDNA explains why the level 
of mutant mtDNA can change during life (16); this may 
depend on the stage of embryonic development in which 
the original mutation occurs.
Point mutations vs large rearrangements
As a general rule, mtDNA can harbour two different 
types of genetic variants, point mutations or large-scale 
rearrangements, which can involve deletions, duplications, 
or both together. Point mutations are commonly mater-
nally inherited and they may differ from non pathogenic 
polymorphisms since a single change of a nucleotide base 
(e.g. A to G in position 3243 commonly for MELAS) (17) 
produces subsequently modifications in the corresponding 
product leading to defects in protein conformation. Several 
mutations in tRNA’s genes (MTT) have been described in 
patients with heart dysfunction as isolated condition or in 
association with other organs involvement, like 3243A > G, 
3260A > G, 3303C > T in the tRNALeu (UUR) gene (MT-
TL1); 4269A > G, 4295A > G, 4300A > G, 4317A > G, 
4320C > T in the tRNAIle gene (MMTI); 8348A > G in the 
tRNALys gene (MTTK), 9997T > C in the tRNAGly gene 
(MTTG), 12297T > C in the tRNA Leu(CUN)(MTTL2) and 
15923A > G in the tRNAThr gene (MTTT). 
The acronimus MIMYCA (Maternally Inherited My-
opathy Myopathy And Cardiomyopathy) has been used in 
some conditions with predominant involvement of skel-
etal and cardiac muscles usually associated to the muta-
tions 3260 A > G or 3303C > T in the tRNALeu (UUR) gene 
(MTTL1). 
Few pathogenic variants of cytochrome b gene (MT-
CYB) have been described as causing a cardiomyopathy 
(see www.mitomap.org). 
Large-scale rearrangements also include partial dele-
tions or duplications of mtDNA (18). They differ from 
point mutations because they span hundreds or thousands 
of nucleotide bases (i.e. 4977 base pair are abrogated in 
the most frequently found “common deletion”). These 
types of mutations are usually sporadic; neither inherited 
nor transmitted to the offspring and they may produce 
Chronic  External  Ophthalmoplegia  (CPEO),  Kearns-
Sayre syndrome or Pearson syndrome. 
They originate during maternal oogenesis or at early 
stages of embryo development (19). Cardiac involvement 
is a rare manifestation of large-scale rearrangements as a 
component of multisystemic syndromes rather than pre-
senting as isolated condition. 
Nuclear genes and their regulation
As we mentioned, mtDNA produces only 13 compo-
nents of the respiratory chain, meaning that most of them 
are codified by nuclear genes, synthesized in the cytosol 
and transported into the organelles. Mutations of nuclear 
genes segregate following mendelian rules, so that mito-
chondrial diseases can be inherited as a dominant, reces-
sive or X-linked traits. The nuclear genes are classified as: 
1) genes involved in the maintenance of mtDNA (POLG1, 
ANT1, PEO1, TK2) (20-24) and producing multiple dele-
tions or depletion of the mtDNA; 2) genes encoding for 
subunits of the respiratory chain complexes (NDUFS2, 
NDUFV2) (25,26); 3) genes regulating the complexes as-
sembly (SURF1, SCO1, SCO2, COX10, COX15) (27,28). 
Mutations in some of these genes have been reported in 
cardiomyopathies, mainly in infants.
ANT1  may  cause  Sengers’  syndrome  (OMIM  no. 
103220)  characterized  by  hypertrophic  cardiomy-
opathy,  congenital  cataract  and,  more  variably,  lactic 
acidemia (29). Also, in mice, it produces exercise intol-
erance, myopathy with “Ragged Red Fibers” (RRF) and 
hypertrophic cardiomyopathy with an evolution to a con-
gestive heart failure (30). 
Mutations  in  SCO2  may  cause  a  neonatal  cardio-
encephalo-myopathy with a severe cytochrome c oxidase 
deficiency.
TAZ G4.5 gene, which codifies for a putative acyl-
transferase, involved in phospholipid biosynthesis, causes 
Barth syndrome, characterized by dilated or hypertrophic 
cardiomyopathy,  endocardial  fibroelastosis  or  left  ven-
tricular noncompaction (LVNC) (31). Others genes like 
FXN gene (Frataxin) in Friedreich ataxia may be associ-
ated with cardiac involvement. 
Cardiological considerations  
in MRCD 
The heart is one of the most frequently affected or-
gans in MRCD’s (35, 36). Cardiac involvement of mul-
tisystem  mitochondrial  disorders  either  manifests  as 
impulse generation or impulse conduction disturbances. Cardiological manifestations of mitochondrial respiratory chain disorders
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or as primary myocardial impairment (hypertrophic or 
dilated cardiomyopathy). Frequent electrocardiographic 
abnormalities are atrial fibrillation, atrioventricular (AV) 
block, Wolff-Parkinson-White  (WPW)  syndrome,  bun-
dle branch blocks, QT prolongation, or ST and T-wave 
anomalies (37).
In addition, in 2007, we reported evidence of a car-
diovascular autonomic impairment in a cohort of patients 
with different mitochondrial disorders (38).
On the other hand, when a mitochondrial condition 
affects selectively the heart, hypertrophic cardiomyopa-
thy (HCM) or dilated mitochondrial cardiomyopathy may 
be clinically indistinguishable from other genetic deter-
mined cardiomyopathies and the onset usually begins in 
the neonatal period (39). 
Cardiac abnormalities are often present in mitochon-
drial syndromes; different patterns of heart involvement 
are described herein and summarized in Table 1. 
Classical mitochondrial syndromes
Kearns-Sayre syndrome (KSS)
This syndrome is characterized by the following triad 
1) onset before the age of 20, 2) pigmentary retinopathy, 
and 3) ophthalmoparesis (40). Other features are usually 
present including cardiac conduction defects, cerebellar 
ataxia, dementia, elevated CSF proteins ( > 100 mg/dl), 
deafness, and low stature. KSS is due to sporadic, single 
large-scale deletions of mtDNA, ranging from 1.3 to 8.8 
kb (90% of the cases) in size, or, rarely, to mtDNA dupli-
cations (41). Calcifications at basal ganglia and thalamus 
or cortical or cerebellar atrophy can be seen by neuroim-
aging studies (42). 
KSS is typically associated with cardiac conduction 
defects with abnormalities on electrocardiogram such as 
PR-interval prolongation, preceding 2nd or 3rd degree AV 
block, His-Ventricular (H-V) interval prolongation due to 
distal disease, dilated cardiomyopathy or Stokes-Adams 
syncope (43). Pacemaker implantation is usually indicat-
ed in these patients despite ventricular arrhythmias have 
been described such as “Torsade de pointes” (44), raising 
the question about which type of device is indicated. In 
addition, patients with KSS with ventricular conduction 
defects also have an accelerated and unpredictable rate of 
progression to complete AV block; sudden death occurs in 
20% of the cases (45). For these reasons, no standard rec-
ommendations are available whether a preventive pace-
maker implantation should be performed before any evi-
dence of electro-cardiologic abnormalities. Some authors 
argue that implantation of defibrillators that simultane-
ously have pacing modes may be the most effective strat-
egy in those patients. As a general rule, all patients with 
KSS should undergo extensive and periodical cardiologic 
examination to determine the presence of conduction ab-
normalities and the appropriate device to be implanted. 
Chronic Progressive External Ophthalmoplegia (CPEO)
CPEO is characterized by a slowly progressive paresis 
of the extra ocular muscles, almost always associated with 
bilateral ptosis. There is often a severe proximal and oro-
pharyngeal muscle weakness. Associations with low stature, 
deafness, diabetes mellitus and depression have also been 
variably described. Age at onset usually ranges in the third or 
fourth decade of life (46). When muscle weakness and exer-
cise intolerance appear, they rarely are debilitating. Sporadic 
single deletion at 4977 bp (namely “common deletion”) is 
the most common cause of sporadic CPEO (47), although 
MTT’s and nuclear gene mutations have also been described, 
respectively in maternal and mendelian (adCPEO, arCPEO) 
variants (48). In CPEO cardiac manifestations are less se-
vere and frequent than in KSS and manifested as partial con-
duction block or isolated ventricular extrasystolia. Periodic 
ECG should be performed in these patients (49). 
Pearson syndrome
This infantile disorder is characterized by refractory 
sideroblastic anaemia and exocrine pancreatic dysfunc-
tion (50). These infants present refractory, transfusion-
dependent, macrocytic anemia, neutropenia, and throm-
bocytopenia. Most of these patients die precociously and 
those who survive may develop, years later, a Kearns-
Sayre  syndrome.  Pearson  syndrome  is  usually  due  to 
heteroplasmic mtDNA deletions with a heteroplasmy rate 
of up to 90% in blood (51). Cardiac involvement is not 
frequently found although left ventricular dilatation and 
heart failure have sporadically been described (52).
Myopathy, encephalopathy, lactic acidosis and stroke-like 
episodes (MELAS)
The key features of this mitochondrial disorder are: 
1) Stroke-like episodes before age 40 with cortical le-
sions, usually in the posterior regions, 2) Dementia and/
or seizures, 3) Proximal muscle weakness with RRF on 
muscle  biopsy  (53).  These  symptoms  can  be  variably 
combined with diabetes mellitus, low stature, deafness, 
cataracts and cardiomyopathy. Frequently, brain strokes 
can be preceded by migraine, fever or seizures and hemi-
paresis, hemianopsia or cortical blindness. Brain injuries 
can be seen as cortical lesions that do not conform to vas-
cular territories, usually on parieto-occipital regions (54). 
Point mutations are frequently found, especially MTTL1 
3243A > G mutation (80% of the cases) (55). Conversely, 
there are at least 12 other distinct pathogenic mtDNA 
gene mutations associated with the MELAS phenotype. 
These include mutations at position 3271 and 3291 in the A. Berardo et al.
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MTTL1 gene, MT-ND1 3308T > C mutation, various MT-
ND5 gene mutations, MT-COXIII 9957T > C mutation, 
and large-scale deletions (56).
Cardiac involvement usually is part of the MELAS 
clinical spectrum (about 38% of patients), but isolated 
adult onset hypertrophic cardiomyopathy caused by MT-
TL1 3243A > G mutation has been reported (57). Heart 
abnormalities include concentric, non-obstructive hyper-
trophic  cardiomyopathy,  dilated  cardiomyopathy,  ar-
rhythmias and sudden death (58, 59). Echocardiographic 
findings could suggest the diagnosis of mitochondrial car-
diomyopathies because they may show a concentric, non-
obstructive hypertrophic pattern, especially when associ-
ated with impaired left ventricle (LV) systolic function 
with a diffuse hypokinesis of wall motion, likely evolving 
to a dilated cardiomyopathy (60). On the other hand, sar-
comeric  genes-related  cardiomyopathies  might  present 
with relative normal LV systolic function and asymmet-
ric LV hypertrophy with increased thickness of the inter-
ventricular septum. Conduction disturbances, including 
Table 1. Clinical features of the main mitochondrial syndromes.




Pigmentosa, onset < 21 years
*Cerebellar ataxia, dementia
*Calcifications at basal ganglia 
and thalamus; cortical or 
cerebellar atrophy
*PR interval prolongation 
preceding 2nd or 3rd degree 
AV block 
*His-ventricular (H-V) interval 








*Common Deletion, 1.3 to 8.8 
kb (90% of the cases)
CPEO *Ophthalmoplegia, ptosis
*Proximal muscle weakness 
and dysphagia
*PR interval prolongation 




*mtDNA point mutations (MTTI, 
MTTL1)
*Nuclear mutations in adCPEO 





anemia and exocrine 
pancreatic dysfunction
*Left ventricular dilatation and 
heart failure
* mtDNA deletions with a 
heteroplasmy rate of up to 
90% in blood
MELAS *Stroke-like episodes before 
age 40 with cortical lesions 
usually in posterior regions 
*Dementia and/or seizures 






*WPW syndrome in both 
childhood and adult patients
*MTTL1 3243A > G(80%), 
3271, 3291
*MT-ND1 3308T > C, various 
MT-ND5 gene mutations, MT-
COXIII 9957T > C 
*Large-scale deletions 
reported
MERRF *Myoclonus, general seizures, 
ataxia, and RRF with 
symptoms usually beginning in 
childhood or in early adulthood
*High prevalence of left 
ventricular dysfunction 
and Wolff-Parkinson-White 
syndrome, an increased 
risk of cardiac death due to 
heart failure in patients with 
myocardial involvement
*MTTK 8344A > G, less 
frequent 8356T > C mutations
Leigh syndrome *Severe subacute 
psychomotor delay and 
necrotizing symmetrical 
lesions in the brainstem, 
thalamus, cerebellum, spinal 
cord and optic nerves
*Elevated lactate in blood 
and CFS
*Hypertrophic or dilated 
cardiomyopathy
*Bradycardia 
*MT-ATPase 6 8993T > G
*Mutations have been 
described in all 14 genes 
coding for core subunits of: 
-Complex I (MT-ND1to6; 
NDUFS1,2,4,7,8; NDUFV1)
-Complex II (SDHA, SDH)
-Complex III (SURF1)
-Others (CoQ10,PDH,SUCLA2)
NARP *Sensory-motor axonal 
neuropathy, ataxia, seizures, 






*MT-ATPase 6 8993T > G, 
8993T > C
*Mutations in Complex I 
subunitsCardiological manifestations of mitochondrial respiratory chain disorders
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Wolff-Parkinson-White  (WPW)  syndrome,  are  present 
not only in infant population but also in adult MELAS pa-
tients (61). Therefore, the presence of cardiomyopathy in 
MELAS should be taken into account because it worsens 
the prognosis, especially in children, and greatly enhanc-
es the importance of a complete cardiological evaluation. 
Myoclonus epilepsy and ragged red fibers (MERRF)
This clinical entity is characterized by myoclonus, 
general seizures, ataxia, and RRF with symptoms usu-
ally beginning in childhood or in early adulthood (62). A 
majority of genetically tested MERRF patients carry the 
mitochondrial MTTK 8344 A > G mutation (63). Other 
symptoms may include deafness, cardiomyopathy, and 
lipomatosis. Onset in childhood is frequently described 
although there have also been late-onset cases. 
Wahbi et al. (64) described in MERRF heart find-
ings similar to the ones reported in MELAS, with a high 
prevalence of left ventricular dysfunction and/or WPW 
syndrome. An increased risk of cardiac death due to heart 
failure in patients with myocardial involvement has also 
been mentioned, especially in patients with an early onset 
of the disease. Interestingly hypertrophic cardiomyopa-
thy was not so frequently found (64). 
Neuropathy, ataxia and pigmentary retinopathy (NARP)
Point  mutations  at  position  8993  (8993T  >  G  and 
8993T > C) of the MT-ATP6 gene cause a neurodegenerative 
disorder, NARP syndrome (Neuropathy, Ataxia and Retini-
tis Pigmentosa) (65). The syndrome can be implemented by 
sensorineural hearing loss, seizures and cognitive impair-
ment (66). The same ATPase 6 point mutations that cause 
NARP syndrome may also cause maternally inherited Leigh 
syndrome (MILS), a sub-acute necrotizing encephalopathy 
that could be a final common phenotype for a number of 
mutations associated with impaired bioenergetic produc-
tion (67). Hypertrophic cardiomyopathy, leading to heart 
failure, is sometimes associated with this condition (68). 
Leigh syndrome
In 1951, Denis Leigh described an infant with severe 
sub-acute psychomotor delay and necrotizing symmetrical 
lesions in the brainstem, thalamus, cerebellum, spinal cord 
and optic nerves (69). This condition is typically seen in in-
fancy and childhood, but adult-onset cases have also been 
reported (70, 71). Clinical sub-acute syndromes that begins 
with ataxia and nystagmus, dystonic features, optic atro-
phy and epilepsy should prompt MRI studies with special 
care to symmetrical brain lesions. Usually, lactate levels 
are increased in blood and CSF. Deficits of the respiratory 
chain (particularly of complexes I, II, IV, or V) or of the 
pyruvate dehydrogenase complex, are responsible of Leigh 
syndrome. Although  several  mutations  in  mtDNA  have 
now  been  described  in  association  with  this  syndrome, 
maternally inherited point mutations in the MT-ATP6 gene 
(m.8993T > G/C and m.9176T > G/C) are the most com-
mon changes (72). Several reports described cardiac abnor-
malities (hypertrophic or dilated cardiomyopathy) in those 
patients, especially in complex I deficiency (68, 73, 74). 
Therapy
Treatment of mitochondrial cardiomyopathies is re-
lated to the different types of heart dysfunction including 
medications, pacemakers, defibrillators or ventricular as-
sist devices (LVADs) implantation or ablation (75).
Drugs such as angiotensin-converting enzyme (ACE) 
inhibitors and beta-blockers have been successfully used 
to treat heart dysfunctions in patients with mitochondrial 
hypertrophic cardiomyopathy (76).
Patients with an isolated heart failure, or with a pre-
dominant cardiac involvement, may benefit from cardiac 
transplantation (77).
Recently,  Arakawa  et  al.,  using  11C-acetate-PET, 
demonstrated that in MELAS patients with a cardiomy-
opathy, there was a rescue of  the impaired TCA-cycle 
metabolism using the L-Arginine, so improving the myo-
cardial oxidative metabolism (78).
Several  palliative  therapeutic  approaches  are  cur-
rently available for patients with mitochondrial cardio-
myopathy i. e. the use of drugs preventing a severe mi-
tochondrial damage (likely caused by oxidative stress) 
and  supplements  protecting  or  restoring  the  OXPHOS 
enzymes. The patients also have to avoid environmental 
agents (i.e. certain types of pesticides) that could inhibit 
mitochondrial function. 
Conclusions
Both  adult  and  infantile  onset  MRCD  patients  can 
have cardiac disturbances characterized by alterations of 
impulse generation, impulse conduction or myocardial im-
pairment, manifesting either as hypertrophic or dilated car-
diomyopathy. In adult patients, some phenotypes tend to 
affect predominantly cardiac muscle and often can be indis-
tinguishable from other genetically determined cardiomy-
opathies. Among the MRCD syndromes, large deletions of 
mtDNA often tend to be associated with conduction distur-
bances. On the other hand, no correlation between the type 
of heart defects and the clinical presentations are observed 
in paediatric patients. Patients with OXPHOS defects who 
present with cardiac manifestations have a poor outcome; 
physicians should be aware of those complications and 
they must perform a complete heart evaluation in all cases 
and suggest an appropriate therapeutic approach. A. Berardo et al.
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